✦ LIBER ✦

Cost-effectiveness analysis of adjuvant docetaxel, doxorubicin, and cyclophosphamide (TAC) for node-positive breast cancer: modeling the downstream effects

✍ Scribed by Heather-Jane Au; Kamran Golmohammadi; Tallal Younis; Shailendra Verma; Stephen Chia; Konrad Fassbender; Philip Jacobs

Publisher: Springer US
Year: 2008
Tongue: English
Weight: 307 KB
Volume: 114
Category: Article
ISSN: 0167-6806
DOI: 10.1007/s10549-008-0034-1

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Cost–effectiveness analysis of adjuvant

Cost–effectiveness analysis of adjuvant therapy for node positive breast cancer in Korea: docetaxel, doxorubicin and cyclophosphamide (TAC) versus fluorouracil, doxorubicin and cyclophosphamide (FAC)

✍ Sang Gyu Lee; Young Geon Jee; Hyun Chul Chung; Sung-Bae Kim; Jungsil Ro; Young-H 📂 Article 📅 2008 🏛 Springer US 🌐 English ⚖ 231 KB

Cost-effectiveness analysis of trastuzum

Cost-effectiveness analysis of trastuzumab in the adjuvant setting for treatment of HER2-positive breast cancer

✍ Louis P. Garrison Jr; Deborah Lubeck; Deepa Lalla; Virginia Paton; Amylou Dueck; 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 209 KB 👁 2 views

## Abstract ## BACKGROUND. Adding trastuzumab to adjuvant chemotherapy provides significant clinical benefit in patients with human epidermal growth factor receptor 2 (HER2)‐positive breast cancer. A cost‐effectiveness analysis was performed to assess clinical and economic implications of adding t

The effect of body mass index on overall

The effect of body mass index on overall and disease-free survival in node-positive breast cancer patients treated with docetaxel and doxorubicin-containing adjuvant chemotherapy: the experience of the BIG 02-98 trial

✍ Evandro de Azambuja; Worta McCaskill-Stevens; Prudence Francis; Emmanuel Quinaux 📂 Article 📅 2009 🏛 Springer US 🌐 English ⚖ 307 KB